Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3438882 | 0.80 | MEN1 (0.34) | — | |
| SCHEMBL3438906 | 0.71 | MEN1 (0.46) | MAPK1 | |
| SCHEMBL3438892 | 0.68 | — | — | |
| SCHEMBL23617444 | 0.67 | GSTO1 (0.36) | GSTO1MAPK1 | |
| SCHEMBL6543221 | 0.66 | — | — | |
| SCHEMBL22517371 | 0.61 | ALDH1A1 (0.44) | MAPK1 | |
| SCHEMBL1246071 | 0.61 | — | — | |
| SCHEMBL9913963 | 0.61 | MAPK1 (0.45) | MAPK1 | |
| SCHEMBL3438885 | 0.61 | — | — | |
| SCHEMBL9387067 | 0.60 | PIK3CD (0.44) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114539106-B | Synthetic method of stable isotope labeled taurinamide hydrochloride | 梯尔希（南京）药物研发有限公司 | 2023-05-02 | — | — | CN | disclosed |
| US-20220186222-A1 | LINKAGE MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2022-06-16 | — | — | US | disclosed |
| US-11155527-B2 | Macromolecules comprising triazoles and related compounds | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-10-26 | — | — | US | disclosed |
| WO-2021030778-A1 | LINKAGE MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | IONIS PHARMACEUTICALS, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| US-20120101271-A1 | DIAMINE SYNTHESIS VIA CATALYTIC C-H AMINATION OF AZIDES | NATIONAL SCIENCE FOUNDATION | 2012-04-26 | — | — | US | disclosed |
| US-20120101271-A1 | DIAMINE SYNTHESIS VIA CATALYTIC C-H AMINATION OF AZIDES | NATIONAL SCIENCE FOUNDATION | 2012-04-26 | — | — | US | disclosed |
| EP-1756089-B1 | MERCAPTOIMIDAZOLES AS CCR2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2008-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101271-A1 | DIAMINE SYNTHESIS VIA CATALYTIC C-H AMINATION OF AZIDES | DOHH, AOC1, ESD | GSTO1 4152/4885MAPK1 3309/4885 |
| US-11155527-B2 | Macromolecules comprising triazoles and related compounds | TUFM, PCNA, MRPS23 | GSTO1 3460/4885MAPK1 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.